Price
$13.50+43.01%Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jacob Chacko
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 111
- Beta
- 0.98
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 13.31
Financials
Net Income
$-48.08MEBITDA
$-51.55MFree Cash Flow
$-41.63MEPS (diluted)
$-0.44Shares Outstanding (diluted)
108.18M+465.2%Operating Expenses
$51.55MCash & Debt
$261.38MReturn of Capital
$1.25MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-129.47M | $-1.47 |
| 2024 | $0.00 | $-127.85M | $-1.83 |
| 2023 | $0.00 | $-100.70M | $-1.96 |
| 2022 | $0.00 | $-89.12M | $-2.25 |
| 2021 | $0.00 | $-78.72M | $-2.07 |
| 2020 | $0.00 | $-73.70M | $-3.36 |
| 2019 | $0.00 | $-26.88M | $-1.40 |
| 2018 | $0.00 | $-21.36M | $-12.32 |
| 2017 | $0.00 | $-22.03M | $-15.62 |
Valuation
ORIChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·6d ago·Neutral
ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 2, 2026 (the “Grant Date”), ORIC granted a total of 14,800 non-qualified stock options and 2,400 restricted stock units to one new non-executive e…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:
View source ↗ - Newsseekingalpha.com·30d ago·Positive
ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript
View source ↗ - Newsmarketbeat.com·30d ago·Neutral
Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalence of baseline brain metastases.
View source ↗ - Newsglobenewswire.com·30d ago·Positive
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses
View source ↗ - Newsglobenewswire.com·30d ago·Positive
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif.
View source ↗ - Newsglobenewswire.com·48d ago·Negative
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data SOUTH SAN FRANCISCO, Cal…
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2026 (the “Grant Date”), ORIC granted a total of 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive …
View source ↗ - Newsseekingalpha.com·67d ago·Positive
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:
View source ↗ - Newsglobenewswire.com·107d ago·Neutral
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 3, 2026 (the “Grant Date”), ORIC granted a total of 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive
View source ↗
Earnings
Mon, Feb 22(in 3 months)
Consensus estimate $-0.42 per share
Typical surprise -4.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.44 vs $-0.39miss
- Mon, Aug 3$-0.38 vs $-0.36miss
- Mon, May 4$-0.34 vs $-0.32miss
- Mon, Feb 23$-0.30 vs $-0.34beat
- Thu, Nov 13$-0.33 vs $-0.41beat
- Tue, Aug 12$-0.47 vs $-0.46miss
Estimates and results for ORIC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ORIC officers and directors.
- Bought
- $263k
- Sold
- $6.7m
2 trades
32 trades
- Piscitelli Dominicsold
- Heyman Richard A.sold
- Heyman Richard A.sold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Piscitelli Dominicsold
- Heyman Richard A.sold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ORIC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
